Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore.
- Author:
Gin Tsen CHAI
1
;
Teck Choon TAN
2
;
Yeong Shyan LEE
3
;
Gregory Jl KAW
3
;
Khoon Leong CHUAH
4
;
Yi Jing LIM
5
;
John Arputhan ABISHEGANADEN
1
;
Bernard Yh THONG
6
Author Information
- Publication Type:Journal Article
- Keywords: idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; quality of health care
- From:Singapore medical journal 2020;61(6):302-307
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTION:The current gold standard for diagnosing interstitial lung disease (ILD) involves an ILD clinic evaluation, followed by discussion in a multidisciplinary meeting (MDM). However, there is a paucity of data on the impact of ILD MDMs on the diagnosis and management of ILDs in Southeast Asia. We studied the clinical impact of the ILD service on the diagnosis and management of ILDs at a university-affiliated tertiary hospital in Singapore.
METHODS:A single-centre retrospective review was done on 97 consecutive patients referred for evaluation to the ILD service from March 2016 to August 2017.
RESULTS:Mean age of the patients was 67 ± 11 years. Gender distribution was almost equal (52% male), with a majority of never-smokers (63%). Mean forced vital capacity (FVC) was 1.81 ± 0.66 L (66% ± 20% predicted). The three commonest referral diagnoses were ILD of uncertain classification (n = 38, 39%), connective tissue disease-associated ILD (CTD-ILD) (n = 24, 25%) and idiopathic pulmonary fibrosis (IPF) (n = 16, 17%). Following evaluation by the ILD service, there was a change of diagnosis in 60 (62%) patients and a change of management in 71 (73%) patients. The majority of consensus MDM diagnoses were IPF (n = 35, 36%), CTD-ILD (n = 30, 30%) and others (n = 15, 15%). There was a significant prognostic separation between the IPF and non-IPF diagnoses made following evaluation by the ILD service.
CONCLUSION:The ILD service allowed for more precise subtyping of various ILDs. This is particularly useful for IPF patients, who can benefit from antifibrotic therapies.
